BioSpace News Archive

Today, the U.S. Supreme Court heard oral arguments in June Medical Services v. Russo--the first abortion rights case to be heard under the current makeup of the Supreme Court.

Vecna Technologies, a leading provider of healthcare information technologies focused on patient solutions and infection surveillance, announced today they will be launching the Vecna mobile app at the upcoming HIMSS20 conference, further enhancing their Patient Self Check-in product suite.

The Pulmonary Fibrosis Foundation (PFF) today announced a new collaboration that could speed up the development of targeted treatments for individuals with idiopathic pulmonary fibrosis (IPF), a devastating and progressive lung disease.

PSAs Highlight COVID-19 Information and Provide Opportunity to Support Response

The Honourable Patty Hajdu, Minister of Health, the Chief Public Health Officer, Dr. Theresa Tam, and the Deputy Chief Public Health Officer, Dr. Howard Njoo, will hold a news conference to provide an update on coronavirus disease..

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, March 11, 2020 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the fourth quarter and full year ended December 31, 2019.

Alopexx Oncology, LLC announced today that it has entered into an exclusive license agreement with Beijing Shenogen Pharma Group to develop and commercialize DI-Leu16-IL2 in China and other parts of Asia.

NEO is pleased to announce that Ceres Acquisition Corp. (“Ceres” or the “Corporation”), a newly formed Special Purpose Acquisition Corporation (“SPAC”), made its Canadian public markets debut on the NEO Exchange.

Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company’s second drug in the central nervous system (CNS) therapeutic area currently in the U.S.